Glyscend Therapeutics
Advancing a new class of oral gut-targeted polymeric drugs for the treatment of T2D and Obesity
Advancing a new class of oral gut-targeted polymeric drugs for the treatment of T2D and Obesity
Glyscend Therapeutics is a biopharmaceutical startup with the slogan "Non-invasive Therapies for Metabolic Disease." Founded in 2014 and headquartered in the United States, the company focuses on developing oral, gut-targeted polymer therapeutics for the treatment of metabolic indications such as type 2 diabetes and other chronic conditions. Their lead drug, designed to replicate the metabolic effects of bariatric surgery, is orally administered, non-absorbed, and gut-restricted duodenal exclusion therapy with safety advantages, avoiding the invasive complications of surgeries and procedures. In June 2020, Glyscend Therapeutics secured a significant $20.50M Series A investment from Santé Ventures and the Medical Research Commercialisation Fund (MRCF). This funding is expected to further support their pioneering work in non-invasive therapies for metabolic diseases, marking a crucial milestone in their quest to revolutionize the treatment landscape for chronic conditions. With its innovative approach and strong investor support, Glyscend Therapeutics is well-positioned to make a significant impact in the biopharmaceutical, biotechnology, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $29.00M | 3 |
-logo.jpg){kind=logo}
|
11 Jun 2020 |
| Seed Round | Unknown | 1 |
|
24 Jul 2019 |
| Grant | $1.20M | 1 |
|
18 Sep 2017 |
| Grant | $500.00K | 1 | Johnson & Johnson Robotics and Digital Solutions | 22 Nov 2016 |
| Grant | $225.00K | 1 |
|
24 Jun 2015 |
No recent news or press coverage available for Glyscend Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
